The PompeQoL questionnaire: Development and validation of a new measure for children and adolescents with Pompe disease

Author:

Truninger Moritz Ilan123ORCID,Werner Helene123ORCID,Landolt Markus Andreas23ORCID,Hahn Andreas4,Hennermann Julia B.5,Lagler Florian B.6,Möslinger Dorothea7,Pfrimmer Charlotte4,Rohrbach Marianne1,Huemer Martina189ORCID

Affiliation:

1. Division of Metabolism, Children's Research Centre University Children's Hospital Zurich, University of Zurich Zurich Switzerland

2. Department of Psychosomatics and Psychiatry University Children's Hospital Zurich Zurich Switzerland

3. Division of Child and Adolescent Health Psychology, Institute of Psychology University of Zurich Zürich Switzerland

4. Department of Child Neurology Justus‐Liebig‐University Gießen Gießen Germany

5. Villa Metabolica, Center for Pediatric and Adolescent Medicine University Medical Center Mainz Mainz Germany

6. Institute for Inherited Metabolic Diseases and Department of Pediatrics Paracelsus Medical University Salzburg Salzburg Austria

7. Department of Paediatrics and Adolescent Medicine Medical University of Vienna Vienna Austria

8. Department of Paediatrics LKH Bregenz Bregenz Austria

9. Competence Area Healthcare and Nursing Vorarlberg University of Applied Sciences Dornbirn Austria

Abstract

AbstractGenetic disorders pose great challenges for affected individuals and their families, as they must cope with the irreversible nature of the disease and a life‐long dependence on medical assistance and treatment. Children and adolescents dealing with Pompe disease (PD) often struggle to keep up with their peers in physical activities. To gain valuable insights into their subjective experiences and better understand their perception and coping related to daily challenges linked to their condition and treatment, the use of standardized questionnaires is crucial. This study introduces the novel PompeQoL 1.0 questionnaire for children and adolescents with PD, designed for comprehensive assessment of both disease‐specific FDH and HRQoL through self‐ and proxy reports. Content validity was ensured through patients' and parents' involvement at the initial stages of development and in subsequent cognitive debriefing process. Participants found the questionnaire easy to understand, answerable, relevant, and comprehensive. Adjustments based on feedback from patients and their parents improved its utility as a patient‐ and observer‐reported outcome measure. After careful item examination, 52 items were selected, demonstrating moderate to excellent test–retest reliability for most scales and initial evidence for satisfactory construct validity. The PompeQoL questionnaire stands as a valuable screening instrument for both clinical and research purposes. Future research should prioritize additional revisions and larger validation studies, focusing on testing the questionnaire in clinical practice and trials. Nevertheless, the PompeQoL 1.0 stands out as the first standardized measure providing insights into disease‐specific FDH and HRQoL among children and adolescents with various forms of PD.

Funder

Sanofi

Publisher

Wiley

Reference33 articles.

1. Online Mendelian Inheritance in Man OMIM®.MIM Number: OMIM#232300: 2023.12.08. World Wide Web.https://omim.org/

2. National Institute of Neurological Disorders and Stroke.What is Pompe disease? Published online 2023. Accessed December 21 2023.https://www.ninds.nih.gov/health-information/disorders/pompe-disease

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3